Annett Schiwitza1, Hans-Ulrich Schildhaus2, Birgit Zwerger3, Josef Rüschoff4, Christian Reinhardt3, Andreas Leha5, Stefan Andreas1,3, Achim Rittmeyer3. 1. Department of Pneumology (Research & Teaching), Universitätsmedizin Göttingen, Göttingen, Germany. 2. Department of Pathology, Universitätsmedizin Göttingen, Göttingen, Germany. 3. LKI Lungenfachklinik Immenhausen, Immenhausen, Germany. 4. Department of Pathology, Pathologie Nordhessen, Kassel, Germany. 5. Department of Medical Statistics, Universitätsmedizin Göttingen, Göttingen, Germany.
Abstract
Aim: Radiological criteria alone do not reflect the entire population benefitting from checkpoint inhibitor therapy (CIT). This study aimed to detect patterns to assess CIT efficacy in non-small-cell lung cancer (NSCLC) patients. Materials & methods: We evaluated clinical, radiological and laboratory parameters in a retrospective cohort of NSCLC patients treated with nivolumab. Results: A total of 51 patients were included in the analysis. Most single parameters failed to reflect treatment benefit. Three laboratory parameters (lactate dehydrogenase, C-reactive protein and the neutrophil/lymphocyte ratio) combined in a weighted score could predict benefit with a sensitivity of 92.3% and a hazard ratio of 0.31 (95% CI: 0.16-0.59) in an early phase of therapy. Sorting patients by score showed a 1-year survival of 36% in those predicted as not benefitting versus 68% in those predicted to benefit. Conclusion: A weighted score integrating common serum markers could help detect patients benefitting from checkpoint inhibitors during ongoing CIT.
Aim: Radiological criteria alone do not reflect the entire population benefitting from checkpoint inhibitor therapy (CIT). This study aimed to detect patterns to assess CIT efficacy in non-small-cell lung cancer (NSCLC) patients. Materials & methods: We evaluated clinical, radiological and laboratory parameters in a retrospective cohort of NSCLCpatients treated with nivolumab. Results: A total of 51 patients were included in the analysis. Most single parameters failed to reflect treatment benefit. Three laboratory parameters (lactate dehydrogenase, C-reactive protein and the neutrophil/lymphocyte ratio) combined in a weighted score could predict benefit with a sensitivity of 92.3% and a hazard ratio of 0.31 (95% CI: 0.16-0.59) in an early phase of therapy. Sorting patients by score showed a 1-year survival of 36% in those predicted as not benefitting versus 68% in those predicted to benefit. Conclusion: A weighted score integrating common serum markers could help detect patients benefitting from checkpoint inhibitors during ongoing CIT.
Authors: Kristin L Ayers; Meng Ma; Gaspard Debussche; David Corrigan; Jonathan McCafferty; Kyeryoung Lee; Scott Newman; Xiang Zhou; Fred R Hirsch; Philip C Mack; Jane J Liu; Eric E Schadt; Rong Chen; Shuyu D Li Journal: BMC Cancer Date: 2021-04-21 Impact factor: 4.430
Authors: Elisabeth Stubenberger; Clemens Aigner; Bahil Ghanim; Anna Rosenmayr; Paul Stockhammer; Melanie Vogl; Ali Celik; Aynur Bas; Ismail Cuneyt Kurul; Nalan Akyurek; Alexander Varga; Till Plönes; Agnes Bankfalvi; Thomas Hager; Martin Schuler; Klaus Hackner; Peter Errhalt; Axel Scheed; Gernot Seebacher; Balazs Hegedus Journal: Sci Rep Date: 2020-04-01 Impact factor: 4.379